文献速递哮喘

重度哮喘生物制剂治疗的临床应答与缓解

Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies.
PubMed 文献 · Chest · 2023-11-03

基于丹麦重度哮喘登记处的全国性观察队列,纳入501例接受生物制剂治疗的成人重度哮喘患者。治疗12个月后397例(79%)达临床应答,其中97例(24%)符合临床缓解标准,相当于全人群的19%;缓解的预测因素为病程较短和BMI较低。

要点

  • 治疗12个月后79%的患者达临床应答,19%达临床缓解。
  • 临床缓解定义为无急性加重、停用维持口服激素、FEV1>80%且ACQ-6≤1.5。
  • 病程较短与BMI较低可预测临床缓解。

核心结论

  • 大多数接受生物制剂治疗的成人重度哮喘患者可获得临床应答,19%在治疗12个月后达到临床缓解。
  • 生物制剂治疗达到临床缓解的长期结局仍需进一步研究。

研究设计与样本

  • 丹麦重度哮喘登记处为全国性队列,纳入丹麦所有接受生物制剂治疗的成人重度哮喘患者。
  • 本观察性队列研究共纳入501例生物制剂初治患者,评估治疗12个月后的应答与缓解。

主要发现

  • 治疗12个月后,501例生物制剂初治患者中104例(21%)无应答,397例(79%)达临床应答。
  • 达临床应答者中97例(24%)符合临床缓解标准,相当于全部患者的19%。
  • 在全部接受生物制剂治疗的患者中,病程较短和BMI较低可预测缓解。

关键数值与推荐

  • 临床应答:治疗12个月后急性加重减少≥50%和/或维持口服糖皮质激素剂量减少≥50%(如需使用)。
  • 临床缓解:治疗12个月后无急性加重、停用维持口服糖皮质激素、FEV1>80%且六项哮喘控制问卷(ACQ-6)评分≤1.5。

临床怎么用

  • 可将临床缓解作为重度哮喘生物制剂治疗的目标之一,并在12个月时评估应答与缓解。
  • 对病程较短、BMI较低的患者可预期更高的缓解可能性。

局限性

  • 为观察性队列研究,未设对照组。
  • 随访时间为12个月,长期结局尚不明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The development of novel targeted biologic therapies for severe asthma has provided an opportunity to consider remission as a new treatment goal. RESEARCH QUESTION: How many patients with severe asthma treated with biologic therapy achieve clinical remission, and what predicts response to treatment? STUDY DESIGN AND METHODS: The Danish Severe Asthma Register is a nationwide cohort including all adult patients receiving biologic therapy for severe asthma in Denmark. This observational cohort study defined "clinical response" to treatment following 12 months as a ≥ 50% reduction in exacerbations and/or a ≥ 50% reduction in maintenance oral corticosteroid dose, if required. "Clinical remission" was defined by cessation of exacerbations and maintenance oral corticosteroids, as well as a normalization of lung function (FEV1 > 80%) and a six-question Asthma Control Questionnaire score ≤ 1.5 following 12 months of treatment. RESULTS: Following 12 months of treatment, 104 (21%) of 501 biologic-naive patients had no response to treatment, and 397 (79%) had a clinical response. Among the latter, 97 (24%) fulfilled the study criteria of clinical remission, corresponding to 19% of the entire population. Remission was predicted by shorter duration of disease and lower BMI in the entire population of patients treated with biologic therapy. INTERPRETATION: Clinical response was achieved in most adult patients initiating biologic therapy, and clinical remission was observed in 19% of the patients following 12 months of treatment. Further studies are required to assess the long-term outcome of achieving clinical remission with biologic therapy.

来源:Chest,查看原文。版权归原作者所有。

引用

  1. Hansen S, Baastrup Søndergaard M, von Bülow A, et al. Clinical Response and Remission in Patients With Severe Asthma Treated With Biologic Therapies. Chest. 2023. PMID: 37925144. doi:10.1016/j.chest.2023.10.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。